Two Sigma Advisers LP Lowers Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Two Sigma Advisers LP lowered its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 8.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 741,118 shares of the company's stock after selling 66,100 shares during the period. Two Sigma Advisers LP owned approximately 1.29% of Ginkgo Bioworks worth $7,278,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares during the last quarter. Forbes J M & Co. LLP boosted its position in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after purchasing an additional 576,732 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Ginkgo Bioworks by 357.4% during the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock worth $6,580,000 after acquiring an additional 523,571 shares in the last quarter. Coastal Bridge Advisors LLC boosted its stake in shares of Ginkgo Bioworks by 1,609.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company's stock worth $2,718,000 after acquiring an additional 260,627 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its stake in shares of Ginkgo Bioworks by 47.9% during the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after acquiring an additional 239,332 shares in the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Down 2.2%

Shares of DNA stock traded down $0.16 during mid-day trading on Thursday, hitting $7.26. 289,878 shares of the stock were exchanged, compared to its average volume of 1,452,693. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $24.85. The company has a market cap of $424.88 million, a PE ratio of -0.55 and a beta of 1.29. The firm has a fifty day moving average of $7.20 and a 200 day moving average of $9.02.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The business had revenue of $48.32 million for the quarter, compared to analysts' expectations of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Equities analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.